What is the initial empiric therapy for septic arthritis?

What is the initial empiric therapy for septic arthritis?

• A. Ceftriaxone and vancomycin
• B. Piperacillin-tazobactam and clindamycin
• C. Vancomycin and cephalexin
• D. Amoxicillin and azithromycin

Answer: (A)

The initial empiric therapy for septic arthritis typically involves the use of broad-spectrum antibiotics that can cover both community-acquired and healthcare-associated infections. Ceftriaxone, a third-generation cephalosporin, is effective against a wide range of gram-negative pathogens, including the strains commonly responsible for septic arthritis, such as Neisseria gonorrhoeae in sexually active individuals and other enteric gram-negative bacteria. Vancomycin is added to this regimen to provide coverage against methicillin-resistant Staphylococcus aureus (MRSA), a significant concern in both community and hospital settings. The combination of ceftriaxone and vancomycin thus ensures adequate coverage against a broad spectrum of potential pathogens responsible for septic arthritis. In comparison to this combination, other options either lack adequate coverage against specific organisms commonly associated with septic arthritis or combine drugs that do not address both gram-positive and gram-negative bacteria effectively. Therefore, the choice of ceftriaxone and vancomycin as an initial empiric therapy is based on their ability to cover the most likely pathogens seen in septic arthritis cases.

The initial empiric therapy for septic arthritis typically involves the use of broad-spectrum antibiotics that can cover both community-acquired and healthcare-associated infections. Ceftriaxone, a third-generation cephalosporin, is effective against a wide range of gram-negative pathogens, including the strains commonly responsible for septic arthritis, such as Neisseria gonorrhoeae in sexually active individuals and other enteric gram-negative bacteria.

Vancomycin is added to this regimen to provide coverage against methicillin-resistant Staphylococcus aureus (MRSA), a significant concern in both community and hospital settings. The combination of ceftriaxone and vancomycin thus ensures adequate coverage against a broad spectrum of potential pathogens responsible for septic arthritis.

In comparison to this combination, other options either lack adequate coverage against specific organisms commonly associated with septic arthritis or combine drugs that do not address both gram-positive and gram-negative bacteria effectively. Therefore, the choice of ceftriaxone and vancomycin as an initial empiric therapy is based on their ability to cover the most likely pathogens seen in septic arthritis cases.